Dr. Reddy's Laboratories Limited (RDY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RDY Revenue Growth
Revenue Breakdown
RDY's revenue distribution by segment and geography
By Geography
RDY Revenue Analysis (2014–2025)
As of May 8, 2026, Dr. Reddy's Laboratories Limited (RDY) generated trailing twelve-month (TTM) revenue of $345.83 billion, reflecting modest growth of +4.4% year-over-year. The most recent quarter (Q3 2026) recorded $87.27 billion in revenue, down 0.9% sequentially.
Looking at the longer-term picture, RDY's 5-year compound annual growth rate (CAGR) stands at +13.3%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $325.54 billion in 2025, representing a new all-time high.
When compared to Healthcare sector peers including SUN (+37.3% YoY), PRGO (-3.6% YoY), and AMRX (+8.0% YoY), RDY has underperformed the peer group in terms of revenue growth. Compare RDY vs SUN →
RDY Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RDYCurrent | $345.8B | +4.4% | +13.3% | 22.1% | |
 SUN | $25.2B | +37.3% | +18.7% | 3.7% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% | |
 TEVA | $17.3B | +4.4% | +0.7% | 12.5% | |
 VTRS | $14.3B | +1.6% | +3.7% | -18.6% |
RDY Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $325.54B | +16.6% | $190.43B | 58.5% | $71.84B | 22.1% |
| 2024 | $279.16B | +13.5% | $163.61B | 58.6% | $67.73B | 24.3% |
| 2023 | $245.88B | +14.7% | $139.34B | 56.7% | $57.14B | 23.2% |
| 2022 | $214.39B | +8288.8% | $113.84B | 53.1% | $29.48B | 13.7% |
| 2021 | $2.56B | -98.5% | $1.30B | 50.8% | $431.4M | 16.9% |
| 2020 | $174.60B | +13.5% | $94.01B | 53.8% | $15.99B | 9.2% |
| 2019 | $153.85B | +8.3% | $83.43B | 54.2% | $20.89B | 13.6% |
| 2018 | $142.03B | +0.9% | $76.30B | 53.7% | $11.92B | 8.4% |
| 2017 | $140.81B | -9.0% | $78.36B | 55.6% | $13.50B | 9.6% |
| 2016 | $154.71B | +4.4% | $92.28B | 59.6% | $29.62B | 19.1% |
Full RDY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See RDY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RDY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RDY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRDY — Frequently Asked Questions
Quick answers to the most common questions about buying RDY stock.
Is RDY's revenue growth accelerating or slowing?
RDY revenue growth slowed to +4.4%, below the 5-year CAGR of +13.3%. TTM revenue is $345.8B. The deceleration marks a shift from historical growth rates.
What is RDY's long-term revenue growth rate?
Dr. Reddy's Laboratories Limited's 5-year revenue CAGR of +13.3% reflects the variable expansion pattern. Current YoY growth of +4.4% is near this long-term average.
How is RDY's revenue distributed by segment?
RDY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.